RU2545757C2 - Биомаркеры - Google Patents

Биомаркеры Download PDF

Info

Publication number
RU2545757C2
RU2545757C2 RU2011121613/15A RU2011121613A RU2545757C2 RU 2545757 C2 RU2545757 C2 RU 2545757C2 RU 2011121613/15 A RU2011121613/15 A RU 2011121613/15A RU 2011121613 A RU2011121613 A RU 2011121613A RU 2545757 C2 RU2545757 C2 RU 2545757C2
Authority
RU
Russia
Prior art keywords
vegfb
levels
patient
thbs1
pgf
Prior art date
Application number
RU2011121613/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2011121613A (ru
Inventor
Иван ДЕВО
Даниэль Р. ВАГНЕР
Франсиско АСУАХЕ
Мелани ВОЗОР
Original Assignee
Сантр Де Решерш Пюблик Де Ля Сантэ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сантр Де Решерш Пюблик Де Ля Сантэ filed Critical Сантр Де Решерш Пюблик Де Ля Сантэ
Publication of RU2011121613A publication Critical patent/RU2011121613A/ru
Application granted granted Critical
Publication of RU2545757C2 publication Critical patent/RU2545757C2/ru

Links

Images

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16Z—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS, NOT OTHERWISE PROVIDED FOR
    • G16Z99/00—Subject matter not provided for in other main groups of this subclass
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
RU2011121613/15A 2008-10-30 2009-10-30 Биомаркеры RU2545757C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10964908P 2008-10-30 2008-10-30
US61/109,649 2008-10-30
PCT/EP2009/064410 WO2010049538A1 (en) 2008-10-30 2009-10-30 Biomarkers

Publications (2)

Publication Number Publication Date
RU2011121613A RU2011121613A (ru) 2012-12-10
RU2545757C2 true RU2545757C2 (ru) 2015-04-10

Family

ID=41528764

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2011121613/15A RU2545757C2 (ru) 2008-10-30 2009-10-30 Биомаркеры

Country Status (9)

Country Link
US (2) US20110294683A1 (pt)
EP (1) EP2362942B1 (pt)
JP (1) JP5749171B2 (pt)
CN (1) CN102203606A (pt)
BR (1) BRPI0920069A8 (pt)
CA (1) CA2741117A1 (pt)
ES (1) ES2640900T3 (pt)
RU (1) RU2545757C2 (pt)
WO (1) WO2010049538A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130116150A1 (en) 2010-07-09 2013-05-09 Somalogic, Inc. Lung Cancer Biomarkers and Uses Thereof
SG2014007454A (en) 2010-08-13 2014-07-30 Somalogic Inc Pancreatic cancer biomarkers and uses thereof
EP2592422A1 (en) * 2011-11-08 2013-05-15 Zora Biosciences OY Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment
EP2592423A1 (en) 2011-11-08 2013-05-15 Zora Biosciences OY Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment
JP2014207883A (ja) * 2013-03-27 2014-11-06 国立大学法人岡山大学 がん幹細胞及びその用途
JP6458009B2 (ja) * 2013-05-31 2019-01-23 コビオレス エヌヴイＣｏｂｉｏｒｅｓ Ｎｖ 心不全処置
EP2843414B1 (en) 2013-08-26 2018-09-19 Roche Diagniostics GmbH Marker for statin treatment stratification in heart failure
CN103487586B (zh) * 2013-09-04 2015-07-15 石家庄洹众生物科技有限公司 一种定量检测可溶性生长刺激表达蛋白2的试验装置
PL228091B1 (pl) * 2014-02-12 2018-02-28 Inst Biochemii I Biofizyki Polskiej Akademii Nauk Zestaw biomarkerów transkryptomicznych do zastosowania w stratyfikacji indywidualnego ryzyka rozwoju pozawałowej niewydolnosci serca, sposób diagnozowania ryzyka wystapienia u pacjenta pozawałowej niewydolnosci serca i zastosowanie biomarkerów do diagnostyki in vitro
WO2015183601A1 (en) * 2014-05-28 2015-12-03 Scripps Health Predictive analysis for myocardial infarction
CN105243294B (zh) * 2015-09-18 2017-06-09 淮南师范学院 一种用于预测癌症病人预后相关的蛋白质对的方法
RU2634375C2 (ru) * 2016-04-18 2017-10-26 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт кардиологии" Способ предупреждения постинфарктного ремоделирования сердца в эксперименте
WO2018009723A1 (en) * 2016-07-06 2018-01-11 Guardant Health, Inc. Methods for fragmentome profiling of cell-free nucleic acids
DE102017116204A1 (de) * 2017-07-18 2019-01-24 Universität Rostock Verfahren zur Vorhersage der Antwort auf die kardiovaskuläre Regeneration
US11708600B2 (en) * 2017-10-05 2023-07-25 Decode Health, Inc. Long non-coding RNA gene expression signatures in disease diagnosis
JP2021174119A (ja) * 2020-04-21 2021-11-01 国立大学法人横浜国立大学 画像生成装置、表示装置、画像生成方法、提示方法およびプログラム
US11854675B1 (en) 2022-10-11 2023-12-26 Flatiron Health, Inc. Machine learning extraction of clinical variable values for subjects from clinical record data
US11915807B1 (en) * 2022-10-11 2024-02-27 Flatiron Health, Inc. Machine learning extraction of clinical variable values for subjects from clinical record data

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000052462A1 (en) * 1999-03-03 2000-09-08 Ludwig Institute For Cancer Research Heart abnormalities in vascular endothelial growth factor b (vegf-b) deficient animals and methods relating to these heart abnormalities
CN1260492A (zh) * 1999-11-09 2000-07-19 赵永同 肿瘤预后评估试剂盒及其制备工艺
CN1139811C (zh) * 1999-11-09 2004-02-25 赵永同 肿瘤早期检测评估试剂盒及其制备工艺
ATE315789T1 (de) * 1999-11-16 2006-02-15 Genentech Inc Elisa für vegf
KR20030021159A (ko) * 2000-05-17 2003-03-12 루드빅 인스티튜트 포 캔서 리서치 종양 세포의 존재 검출 및 항-종양제에 대한 스크리닝 방법
CA2451311A1 (en) * 2001-06-20 2003-01-03 Ludwig Institute For Cancer Research Stimulation of vascularization with vegf-b
AU2002356033A1 (en) * 2001-08-13 2003-03-03 Genetics Development Corporation A molecular diagnostic and computerized decision support system for selecting the optimum treatment for human cancer
US20030096248A1 (en) * 2001-09-04 2003-05-22 Vitivity, Inc. Diagnosis and treatment of vascular disease
ATE394679T1 (de) * 2002-11-16 2008-05-15 Dade Behring Marburg Gmbh Scd40l, papp-a und plazentaler-wachstumsfaktor (pigf) als biochemische markerkombinationen bei kardiovaskulären erkrankungen
CN101426489A (zh) * 2004-04-16 2009-05-06 曹义海 抑制血管生成的成分和方法
TW200732347A (en) * 2005-10-06 2007-09-01 Trophogen Inc VEGF analogs and methods of use

Also Published As

Publication number Publication date
JP5749171B2 (ja) 2015-07-15
WO2010049538A1 (en) 2010-05-06
CN102203606A (zh) 2011-09-28
BRPI0920069A8 (pt) 2017-10-03
JP2012507026A (ja) 2012-03-22
EP2362942B1 (en) 2017-06-21
US20110294683A1 (en) 2011-12-01
RU2011121613A (ru) 2012-12-10
BRPI0920069A2 (pt) 2017-06-06
US20160188835A1 (en) 2016-06-30
ES2640900T3 (es) 2017-11-07
CA2741117A1 (en) 2010-05-06
EP2362942A1 (en) 2011-09-07

Similar Documents

Publication Publication Date Title
RU2545757C2 (ru) Биомаркеры
US20230184760A1 (en) Marker combinations for diagnosing infections and methods of use thereof
EP3350345B1 (en) Biomarkers for heart failure
US11226333B2 (en) Lung cancer signature
JP2019207249A (ja) 心血管系のリスクイベントの予測及びその使用
JP2021097669A (ja) 慢性心不全の診断と予後予測の方法
JP2011515666A (ja) トリプルネガティブ乳がんに関連するｄｎａ修復タンパク質およびその使用法
WO2019099706A1 (en) Markers for the diagnosis and treatment of non-alcoholic steatohepatitis (nash) and advanced liver fibrosis
US11220717B2 (en) Biomarkers for prospective determination of risk for development of active tuberculosis
US10078089B2 (en) Compositions and methods for treating steroid resistant nephrotic syndrome and/or steroid sensitive nephrotic syndrome
US20220298574A1 (en) Blood biomarkers for appendicitis and diagnostics methods using biomarkers
US10584383B2 (en) Mitochondrial non-coding RNAs for predicting disease progression in heart failure and myocardial infarction patients
US20200399698A1 (en) Methods of determining response to tnf alpha blockers
CN112011604B (zh) 一种用于评估重症肌无力风险的微生物标志物及其应用
US20240044902A1 (en) Methods for the detection and treatment of ovarian cancer
CN116254335A (zh) Adam12生物标志物在冠状动脉扩张症诊断中的应用
US20130310275A1 (en) Diagnosis of asymptomatic left ventricular systolic dysfunction

Legal Events

Date Code Title Description
PD4A Correction of name of patent owner